The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Pathological growth of cardiomyocytes (hypertrophy) is a major determinant for the development of heart failure, one of the leading medical causes of mortality worldwide. Here we show that the microRNA (miRNA)-212/132 family regulates cardiac hypertrophy and autophagy in cardiomyocytes. Hypertrophic stimuli upregulate cardiomyocyte expression of miR-212 and miR-132, which are both necessary and sufficient to drive the hypertrophic growth of cardiomyocytes. MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice. Both miR-212 and miR-132 directly target the anti-hypertrophic and pro-autophagic FoxO3 transcription factor and overexpression of these miRNAs leads to hyperactivation of pro-hypertrophic calcineurin/NFAT signalling and an impaired autophagic response upon starvation. Pharmacological inhibition of miR-132 by antagomir injection rescues cardiac hypertrophy and heart failure in mice, offering a possible therapeutic approach for cardiac failure. Heart failure is often a consequence of pathological growth of cardiomyocytes or cardiac hypertrophy. Here Ucar and colleagues report that the microRNAs miR-132 and miR-212 promote cardiac hypertrophy and inhibit autophagy in cardiomyocytes by downregulating the transcription factor FoxO3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, fine-tuning of FOXO3 levels has been achieved via a miRNA-132 antagonistic approach,157 that is currently clinically tested (NCT04045405).”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [157]
In the citing paper
“| Cardiomyopathies | Cardiomyocyte‐specific overexpression of miR‐212/132 | Pathological cardiac hypertrophy, heart failure, and premature death, after impaired autophagic response upon starvation | Ucar et al (2012) |”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al (2012)
In the citing paper
“Along similar lines, the cardiomyocyte‐specific overexpression of miRNAs invalidating the transcriptional activity of FOXO3 (Ucar et al, 2012) or activating MTORC1 (Li et al, 2017) precipitates cardiac function, leading to heart failure.”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Self-citationHomeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Control of translation and mRNA degradation by miRNAs and siRNAs: Table 1.
Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., & Parker, R. (2006) · Genes & Development · doi:10.1101/gad.1399806 · Cited by 2,060
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.019 · Cited by 1,590
Cited by
Items 201–300 of 609
Noncoding RNAs in Heart Failure
Dangwal, S., Schimmel, K., Foinquinos, A., Xiao, K., & Thum, T. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_99 · Cited by 46
“Hence, the discovery of the pro-hypertrophic, evolutionarily conservedmiR-212/132 familywas of great importance (Ucar et al. 2012).”
BackgroundSelf-citationWang, X.-T., Wu, X., Lu, Y., Sun, Y., Zhu, H.-H., Liang, J.-B., He, W., Zeng, Z., & Li, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485905 · Cited by 43
The Impact of microRNAs in Renin–Angiotensin-System-Induced Cardiac Remodelling
Adamcová, M., Kawano, I., & Šimko, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094762 · Cited by 45
Huang, S., Zou, X., Zhu, J.-N., Fu, Y., Lin, Q., Liang, Y., Deng, C., Kuang, S., Zhang, M., Liao, Y., et al. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12445 · Cited by 42
Shah, R. V., Ziegler, O., Yeri, A., Liu, X., Murthy, V. L., Rabideau, D. J., Xiao, C. Y., Hanspers, K., Belcher, A. M., Tackett, M., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004278 · Cited by 41
“Biventricular pacemaker 40% (61) 39% (34) 42% (27) 0.”
Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212
Sárközy, M., Gáspár, R., Zvara, Á., Siska, A., Kovari, B. P., Szűcs, G., Márványkövi, F. M., Kovács, M. G., Diószegi, P., Bodai, L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37690-5 · Cited by 47
Self-citationMicroRNAs in heart failure: Small molecules with major impact
Kalozoumi, G., Yacoub, M. H., & Sanoudou, D. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.30 · Cited by 43
“These data indicate a causal role of miR-132 and a contributing role of miR-212 in the development of hypertrophy and HF in vivo, whilst suppression of miR-132 via antagomiRs emerges as a possible therapeutic approach for HF.(103) In contrast, inhibition of endogenous miR-21 or miR-18b was shown to increase hypertroph…”
BackgroundInfluentialMicroRNA Mechanisms of Action: What have We Learned from Mice?
Jin, H. Y., & Xiao, C. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00328 · Cited by 49
“…Dong et al., 2012; Gurha et al., 2012; Horie et al., 2012, 2013; Hsu et al., 2012; Liang et al., 2012, 2015; Mori et al., 2012; Tsai et al., 2012; Ucar et al., 2012; Wei et al., 2012, 2014; Zhuang et al., 2012; Belkaya et al., 2013; Bian et al., 2013; Danielson et al., 2013; Dorhoi et al.,…”
Shao, H., Yang, L., Wang, L., Tang, B., Wang, J., & Li, Q. (2017) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0158 · Cited by 41
Regulatory RNAs and Cardiovascular Disease – With a Special Focus on Circulating MicroRNAs
Dlouhá, D., & Hubacek, J. A. (2017) · Physiological Research · doi:10.33549/physiolres.933588 · Cited by 42
“The neurologically enriched miR-212/132 family becomes activated during heart failure (HF) in human and animal models and has been shown to regulate cardiac hypertrophy in cardiomyocytes (Ucar et al. 2012).”
Khidr, E. G., Abulsoud, A. I., Doghish, A. A., El‐Mahdy, H. A., Ismail, A. M. A., Elballal, M. S., Sarhan, O. M., Mageed, S. S. A., Elsakka, E. G. E., Elkhawaga, S. Y., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154624 · Cited by 43
The Roles of microRNAs in the Cardiovascular System
Nappi, F., Singh, S., Jitendra, V., Alzamil, A., & Schoell, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814277 · Cited by 52
“With regard to cardiovascular therapies, this drug could be the first to target miRNAs [9 With regard to cardiovascular therapies, this drug could be the first to target miRNAs [9,22,25,101].”
Crozatier, B., & Ventura‐Clapier, R. (2015) · Circulation · doi:10.1161/circulationaha.114.013895 · Cited by 43
Ali, T., Mushtaq, I., Maryam, S., Farhan, A., Saba, K., Jan, M. I., Sultan, A., Anees, M., Duygu, B., Hamera, S., et al. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.007 · Cited by 40
Non‐coding RNAs: key players in cardiac disease
Kreutzer, F. P., Fiedler, J., & Thum, T. (2019) · The Journal of Physiology · doi:10.1113/jp278131 · Cited by 41
Self-citationSu, B., Wang, X., Sun, Y., Long, M., Zheng, J., Wu, W., & Li, L. (2020) · BioMed Research International · doi:10.1155/2020/7231243 · Cited by 40
“miRNAs regulate autophagy and apoptosis by modulating gene expression in cardiomyocytes [27, 28].”
BackgroundResistin deletion protects against heart failure injury by targeting DNA damage response
Zhao, B., Bouchareb, R., & Lebeche, D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab234 · Cited by 43
Targeting microRNAs in heart failure
Duygu, B., Windt, L. J. D., & Martins, P. A. D. C. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.008 · Cited by 43
“microRNA-212/132: The miR-212/132 microRNA family is upregulated in both murine and human failing hearts [56].”
BackgroundInfluentialDiniz, G. P., Lino, C. A., Guedes, E. C., Moreira, L. D. N., & Barreto‐Chaves, M. L. M. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0504-7 · Cited by 40
“It is becoming increasingly apparent that several miRNAs are directly involved in cardiac hypertrophy development [34], including miR-212/132 [39], miR-22 [22], miR-208a [31], miR-27b [42] and miR-378 [19].”
BackgroundMiRNA Deregulation in Cardiac Aging and Associated Disorders
Verjans, R., van Bilsen, M., & Schroen, B. L. M. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.004 · Cited by 41
Xu, X., Wang, J., & Wang, X. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s245199 · Cited by 39
Duan, Y., Chen, B., Chen, F., Yang, S., Zhu, C., Ma, Y., Li, Y., & Shi, J. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16280 · Cited by 42
Advances in miR-132-Based Biomarker and Therapeutic Potential in the Cardiovascular System
Xu, K., Chen, C., Wu, Y., Wu, M., & Lin, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751487 · Cited by 41
Epigenetic Regulation Associated With Sirtuin 1 in Complications of Diabetes Mellitus
Wang, J., Wang, S., Wang, J., Xiao, M., Guo, Y., Tang, Y., Zhang, J., & Gu, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.598012 · Cited by 44
The myriad essential roles of microRNAs in cardiovascular homeostasis and disease
Neppl, R. L., & Wang, D. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.06.003 · Cited by 36
Therapeutic targeting of autophagy in myocardial infarction and heart failure
Riquelme, J. A., Chávez, M. N., Mondaca‐Ruff, D., Bustamante, M., Vicencio, J. M., Quest, A. F. G., & Lavandero, S. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1202760 · Cited by 38
Between Inflammation and Autophagy: The Role of Leptin-Adiponectin Axis in Cardiac Remodeling
Kamareddine, L., Ghantous, C. M., Allouch, S., Ashmar, S. A., Anlar, G. G., Kannan, S., Djouhri, L., Korashy, H. M., Agouni, A., & Zeidan, A. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s322231 · Cited by 51
Programmed Cell Death: Complex Regulatory Networks in Cardiovascular Disease
Zhou, L., Sun, J., Gu, L., Wang, S., Yang, T., Wei, T., Shan, T., Wang, H., & Wang, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.794879 · Cited by 39
Olejnik, A., Radajewska, A., Krzywonos‐Zawadzka, A., & Bil‐Lula, I. (2023) · Scientific Reports · doi:10.1038/s41598-023-47686-5 · Cited by 42
Role of noncoding RNAs in regulation of cardiac cell death and cardiovascular diseases
Dong, Y., Liu, C.-Y., Zhao, Y., Ponnusamy, M., Li, P., & Wang, K. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2640-8 · Cited by 36
Exploring the Continuum of Hypertrophic Cardiomyopathy—From DNA to Clinical Expression
Popa‐Fotea, N., Micheu, M. M., Bătăilă, V., Scafa‐Udriște, A., Dorobantu, L. F., Scărlătescu, A. I., Zamfir, D., Stoian, M., Onciul, S., & Dorobanţu, M. (2019) · Medicina · doi:10.3390/medicina55060299 · Cited by 43
Sheikh, M. S. A., Salma, U., Zhang, B., Chen, J., Zhuang, J., & Ping, Z. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/5893064 · Cited by 34
“However, pharmacological inhibition of miR-132 by intravenous antagomir injection rescues cardiac hypertrophy and pressure-overload-induced HF in mice, offering a novel therapeutic approach for cardiac failure [87].”
BackgroundYu, P., Zhang, Y., Li, C., Li, Y., Jiang, S., Zhang, X., Ding, Z., Tu, F., Wu, J., Gao, X., et al. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12547 · Cited by 36
“Pathological cardiac hypertrophy often precedes and develops to heart failure, which is one of the leading medical causes of morbidity and mortality worldwide [1].”
BackgroundCaria, A. C. I., Aras, M. G., Nascimento, L., Sousa, R. A. L. D., Aras, R., & Souza, B. S. D. F. (2021) · Biomolecules · doi:10.3390/biom11121771 · Cited by 35
“generating LVH, in both, in the culture of primary cardiomyocytes with different hypertrophic stimuli and in mice with transaortic constriction (TAC) and cardiac hypertrophy [40].”
BackgroundManipulation of Autophagy in Cancer Cells: An Innovative Strategy to Fight Drug Resistance
Aredia, F., & Scovassi, A. I. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.85 · Cited by 33
Li, L., Huang, C., He, Y., Sang, Z., Liu, G., & Dai, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000492300 · Cited by 37
Mo, B., Wu, X., Wang, X., Xie, J., Ye, Z., & Li, L. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.31099 · Cited by 36
“Previous studies have also reported that autophagy is related to the occurrence and process of most cardiovascular diseases [9].”
BackgroundSelective Heart Irradiation Induces Cardiac Overexpression of the Pro-hypertrophic miR-212
Sárközy, M., Gáspár, R., Zvara, Á., Kiscsatári, L., Varga, Z., Kovari, B. P., Kovács, M. G., Szűcs, G., Fábián, G., Diószegi, P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00598 · Cited by 37
“MiR212 was shown to be a key regulator of the development of LVH and heart failure via the repression of the antihypertrophic transcription factor FOXO3 and overactivation of the calcineurin/NFAT signaling during heart failure development (22).”
BackgroundMethodInfluentialSelf-citationLi, X., Le, H. T., Sato, F., Kang, T. H., Makishima, M., Zhong, L., Liu, Y. F., Guo, L., & BHAWAL, U. K. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.058 · Cited by 34
Targeting epigenetics in diabetic cardiomyopathy: Therapeutic potential of flavonoids
Zhou, Y., Suo, W., Zhang, X., Yang, Y., Zhao, W., Li, H., & Ni, Q. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114025 · Cited by 36
Zhu, M., Wang, H.-R., Han, F.-X., Cai, Z.-L., Wang, J., & Guo, M. (2023) · Aquatic Toxicology · doi:10.1016/j.aquatox.2023.106780 · Cited by 37
Eskildsen, T. V., Schneider, M., Sandberg, M. B., Skov, V., Brønnum, H., Thomassen, M., Kruse, T. A., Andersen, D. C., & Sheikh, S. P. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320314539367 · Cited by 35
Klotho Protein and Cardio-Vascular System
Tyurenkov, I. N., Perfilova, V. N., Нестерова, А. А., & Glinka, Y. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921020024 · Cited by 40
miR-132/212 Impairs Cardiomyocytes Contractility in the Failing Heart by Suppressing SERCA2a
Lei, Z., Wahlquist, C., el Azzouzi, H., Deddens, J. C., Kuster, D. W. D., van Mil, A., Rojas‐Muñoz, A., Huibers, M. M. H., Mercola, M. A., de Weger, R. A., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.592362 · Cited by 37
“This miR-132/212 family regulates cardiac function in the failing mouse heart, and pharmaceutically inhibition of miR-132 is beneficial for heart failure (11, 13, 14).”
BackgroundResultMolecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy
Mittal, A., Garg, R., Bahl, A., & Khullar, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.725532 · Cited by 34
“miRNA-212 was found to regulate the process of cardiac hypertrophy by directly regulating Forkhead box O3 (Foxo3) (35).”
BackgroundZhou, J., Gao, J., Zhang, X., Liu, Y., Gu, S., Zhang, X., An, X., Yan, J., Yue, X., & Su, P. (2015) · International Heart Journal · doi:10.1536/ihj.14-386 · Cited by 32
Non‐coding RNAs in cardiac hypertrophy
Ottaviani, L., & Martins, P. A. D. C. (2017) · The Journal of Physiology · doi:10.1113/jp273129 · Cited by 33
“…through treatment of animals with an antagomir confers protection from cardiac hypertrophic growth and from eventual development into heart failure (Ucar et al. 2012). miR-199b, in turn, not only targets calcineurin–NFAT signalling but is also regulated by NFAT itself (da Costa Martins et al.…”
BackgroundWang, L., Ye, N., Lian, X., Peng, F., Zhang, H., & Gong, H. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.019 · Cited by 32
Zhang, J., Wei, X., Zhang, W., Wang, F., & Li, Q. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172941 · Cited by 32
FGF13 Is a Novel Regulator of NF-κB and Potentiates Pathological Cardiac Hypertrophy
Sun, J. M., Niu, C., Ye, W., An, N., Chen, G., Huang, X., Wang, J., Chen, X., Shen, Y., Huang, S., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101627 · Cited by 34
Circular RNAs in Alzheimer’s Disease: A New Perspective of Diagnostic and Therapeutic Targets
Vakili, O., Asili, P., Babaei, Z., Mirahmad, M., Keshavarzmotamed, A., Asemi, Z., & Mafi, A. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220829164211 · Cited by 36
miR-96 attenuates status epilepticus-induced brain injury by directly targeting Atg7 and Atg16L1
Gan, J., Cai, Q., Qu, Y., Zhao, F., Wan, C., Luo, R., & Mu, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-10619-0 · Cited by 33
Stargazing microRNA maps a new miR-21 star for cardiac hypertrophy
Indolfi, C., & Curcio, A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75801 · Cited by 31
“Cardiomyocyte-specific overexpression of the miR-212/132 family targets the antihypertrophic and proau-tophagic FOXO3 transcription factor and leads to pathological cardiac hypertrophy, HF, and death in mice, whereas animals lacking miR-212/132 are protected from pressure overload–induced HF (12).”
BackgroundMicroRNA regulation of autophagy in cardiovascular disease
Zhu, H. (2016) · Frontiers in bioscience · doi:10.2741/4471 · Cited by 33
“Suppression rescues pressure over-load induced hypertrophy (98)”
BackgroundPivotal role of microRNAs in cardiac physiology and heart failure
Leite-Moreira, A. M., Lourenço, A. P., Falcão‐Pires, I., & Leite-Moreira, A. F. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.025 · Cited by 33
miR-22 regulates starvation-induced autophagy and apoptosis in cardiomyocytes by targeting p38α
Li, G., Wang, G., Ma, L., Guo, J., Song, J., Ma, L., & Zhao, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.086 · Cited by 30
Cell-Based Mechanosensation, Epigenetics, and Non-Coding RNAs in Progression of Cardiac Fibrosis
Ferrari, S., & Pesce, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010028 · Cited by 31
Wang, H., Li, J., Xu, T., Yao, H., Chen, G., & Hu, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11195 · Cited by 31
“ucar et al (57) identified that mirna-212/132 knockout mice have upregulated autophagy and significantly decreased myocardial hypertrophy.”
BackgroundDecoding microRNA drivers in atherosclerosis
Vartak, T., Kumaresan, S., & Brennan, E. P. (2022) · Bioscience Reports · doi:10.1042/bsr20212355 · Cited by 31
Current RNA strategies in treating cardiovascular diseases
Chia, S. P. S., Pang, J. K. S., & Soh, B.-S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.028 · Cited by 34
Non-coding RNAs as orchestrators of autophagic processes
Gupta, S. K., & Thum, T. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.012 · Cited by 30
“MiR-212/132 directly targets the pro-autophagic and anti-hypertrophic transcription factor FoxO3a and thus inhibits cardiac autophagy [21].”
BackgroundInfluentialSelf-citationJin, L., Zhou, Y., Han, L., & Piao, J. (2019) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00417-5 · Cited by 31
“Over the decades, scientists have shown a great interest in the role of miRNAs in regulating human diseases including cardiac hypertrophy and heart failure (Mann 2007; van Rooij et al. 2007; da Costa Martins Paula et al. 2008; Li and Rana 2014).”
BackgroundCircular RNAs; powerful microRNA sponges to overcome diabetic nephropathy
Mafi, A., Yadegar, N., Salami, M., Salami, R., Vakili, O., & Aghadavod, E. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153618 · Cited by 30
MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy
Chiti, E., Paolo, M. D., Turillazzi, E., & Rocchi, A. (2021) · Diagnostics · doi:10.3390/diagnostics11091720 · Cited by 31
Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?
Philippen, L. E., Dirkx, E., Wit, J. B. M., Burggraaf, K., Windt, L. J. D., & Martins, P. A. D. C. (2015) · Molecular Therapy · doi:10.1038/mt.2015.133 · Cited by 36
Molecular Targets in the Treatment of Cardiac Hypertrophy
Kühn, C., Hille, S. S., & Frey, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_18 · Cited by 29
Activation of common signaling pathways during remodeling of the heart and the bladder
Koeck, I., Burkhard, F. C., & Monastyrskaya, K. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.09.012 · Cited by 30
Shear Stress in Autophagy and Its Possible Mechanisms in the Process of Atherosclerosis
Guo, F., Hu, Y., Zheng, L., & Wang, Q. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3649 · Cited by 31
“Autophagy (literally ‘‘self-eating’’) is highly conserved in mammals and plays an important role in the intracellular protective process and is induced by various types of stress, such as cellular stress, reactive oxygen species (ROS), starvation, accumulation of protein aggregates, or damaged organelles (Ucar et al.,…”
BackgroundLinthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 33
Self-citationHarnessing fetal and adult genetic reprograming for therapy of heart disease.
Nandi, S. S., & Mishra, P. K. (2015) · PubMed · Cited by 35
Li, G., Song, Y., Li, Y., Jie, L., Wu, W., Li, J.-Z., Zhang, Q., & Wang, Y. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0132 · Cited by 32
Kokkonen-Simon, K. M., Saberi, A., Nakamura, T., Ranek, M. J., Zhu, G., Bedja, D., Kühn, M., Halushka, M. K., Lee, D. I., & Kass, D. A. (2018) · JCI Insight · doi:10.1172/jci.insight.121739 · Cited by 27
Zhang, X., Zhang, M., & Wang, C.-T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.065 · Cited by 28
Du, J., Liu, Y., & Fu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4272-5_16 · Cited by 31
Large Animal Models of Cell-Free Cardiac Regeneration
Spannbauer, A., Mester-Tonczar, J., Traxler, D., Kastner, N., Zlabinger, K., Hašimbegović, E., Riesenhuber, M., Pávó, N., Goliasch, G., & Gyöngyösi, M. (2020) · Biomolecules · doi:10.3390/biom10101392 · Cited by 26
“The miR‐212/132 cluster has been identified as a critical regulator of cardiac hypertrophy and cardiomyocyte autophagy [47].”
BackgroundMyocardial Infarction: The Protective Role of MiRNAs in Myocardium Pathology
Wang, W., & Zheng, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.631817 · Cited by 32
“A study suggested that intravenous miR-144 has a potent effects on cardiac remodeling of rats with MI, which was associated with significant changes in autophagy signaling (100).”
BackgroundNon-coding RNAs in cardiac regeneration: Mechanism of action and therapeutic potential
Wang, Y., Chen, J., Cowan, D. B., & Wang, D. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.07.007 · Cited by 28
Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease
Robinson, E. L., & Port, J. D. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.02.003 · Cited by 31
“In turn, many of these pathways can affect cardiac biology in terms of modulating cellular hypertrophy and autophagy.(80) Working initially in cell culture models, Ucar et al(80) demonstrated that miR-212/132 null mice were substantially protected from pressure overload–induced HF, reducing end-systolic and -diastolic…”
BackgroundWIPI1 is a conserved mediator of right ventricular failure
Tzimas, C., Rau, C. D., Bürgisser, P. E., Jean-Louis, G., Lee, K., Chukwuneke, J., Dun, W., Wang, Y., & Tsai, E. J. (2019) · JCI Insight · doi:10.1172/jci.insight.122929 · Cited by 32
Tschöpe, C., Linthout, S. V., & Kherad, B. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0874-6 · Cited by 27
Roles of non-coding RNA in diabetic cardiomyopathy
Yao, X., Huang, X., Chen, J., Lin, W., & Tian, J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02252-9 · Cited by 28
MicroRNAs in Heart Failure: New Targets in Disease Management
Elzenaar, I., Pinto, Y. M., & van Oort, R. J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.138 · Cited by 26
Sadegh, M. K., Ekman, M., Krawczyk, K., Svensson, D., Göransson, O., Dahan, D., Nilsson, B., Albinsson, S., Uvelius, B., & Swärd, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116784 · Cited by 27
“Work in the heart, finally, has shown that miR-132 and miR-212 are involved in hypertrophy [14].”
BackgroundmicroRNA‐25 promotes cardiomyocytes proliferation and migration via targeting Bim
Qin, X., Gao, S., Yang, Y., Wu, L., & Wang, L. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28773 · Cited by 26
“Downregulation of miR‐132 rescued cardiac hypertrophy and heart failure in mice (Ucar et al., 2012). miR‐25 belongs to the miR‐106b‐25 cluster that is located in intron 13 of the MCM7 oncogene on chromosome 7q22.”
BackgroundMicroRNAs and Calcium Signaling in Heart Disease
Park, J., & Kho, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910582 · Cited by 27
MicroRNA-34a: A Novel Therapeutic Target in Fibrosis
Zhao, M., Qi, Q., Liu, S., Huang, R. S., Shen, J., Zhu, Y., Chai, J., Zheng, H., Wu, H., & Liu, H. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.895242 · Cited by 30
Advanced research on the microRNA mechanism in heart failure
Deng, J., & Zhong, Q. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.185 · Cited by 26
Role of Oxidative Stress in Heart Failure: Insights from Gene Transfer Studies
Geest, B. D., & Mishra, M. (2021) · Biomedicines · doi:10.3390/biomedicines9111645 · Cited by 30
“MiR-132 also directly targets the anti-hypertrophic and pro-autophagic Forkhead box O3 (FOXO3) transcription factor [116].”
BackgroundHuang, S., Zhou, Y., Zhang, Y., Liu, N., Liu, J., Liu, L., & Fan, C. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07492-7 · Cited by 27
“And the antago-miR-132 injection rescued HF in mice [23].”
MicroRNA-Mediated Autophagic Signaling Networks and Cancer Chemoresistance
Pan, B., Yi, J., & Song, H. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1460 · Cited by 25
“21 Second, the vesicle nucleation is mediated by activation of the Beclin-1-class III phosphatidylinositol 3-kinase ( PI3KCIII , an ortholog of Vps14 )- Vps15 core complex and other proteins 22 (Fig.”
Autophagy-associated signal pathways of functional foods for chronic diseases
Xie, J., Liang, J., & Chen, N. (2019) · Food Science and Human Wellness · doi:10.1016/j.fshw.2019.03.002 · Cited by 27
Herdoiza Padilla, E., Crauwels, P., Bergner, T., Wiederspohn, N., Förstner, S., Rinas, R., Ruf, A., Kleemann, M., Handrick, R., Tuckermann, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02210 · Cited by 25
“Furthermore, gain-offunction high-throughput screenings have allowed identification of miRNAs involved in cancer (20–22), cardiopathology (23, 24), as well as their characterization as biomarker candidates (25).”
BackgroundPharmacology of heart failure: From basic science to novel therapies
Lother, A., & Hein, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.004 · Cited by 25
Roles of MicroRNAs in Glucose and Lipid Metabolism in the Heart
Du, H., Zhao, Y., Li, H., Wang, D. W., & Chen, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.716213 · Cited by 24
Intercellular transfer of miR-200c-3p impairs the angiogenic capacity of cardiac endothelial cells
Ottaviani, L., Juni, R. P., de Abreu, R. C., Sansonetti, M., Sampaio‐Pinto, V., Halkein, J., Hegenbarth, J. C., Ring, N., Knoops, K., Kocken, J. M. M., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.002 · Cited by 28
MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far
Roma‐Rodrigues, C., Raposo, L. R., & Fernandes, A. R. (2015) · BioMed Research International · doi:10.1155/2015/983290 · Cited by 26
“The possibility of the use of miRNAs based therapy in treatment of HCM is highlighted by several in vivo studies [46, 66, 67] that were able to inhibit cardiomyocyte hypertrophy and fibrosis (Table 2).”
BackgroundMethodThe Role of MicroRNAs in the Cardiac Response to Exercise
Liu, X., Platt, C., & Rosenzweig, A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029850 · Cited by 24
Pleiotropic cardiac functions controlled by ischemia-induced lncRNA H19
Hobuß, L., Foinquinos, A., Jung, M., Kenneweg, F., Xiao, K., Wang, Y., Zimmer, K., Remke, J., Just, A., Nowak, J., et al. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.07.001 · Cited by 25
Self-citationZuo, H., Li, L., Wang, X., Chen, S., Liao, Z., Wei, S., Ruan, H., Li, T., & Chen, J. (2022) · Hypertension Research · doi:10.1038/s41440-022-01111-y · Cited by 24
“To date, various miRNAs, such as miRNA-212/132, miR199a, miR-378 [20], and miR-146a [21], are known to be key modulators in pathological cardiac hypertrophy [22, 23].”
BackgroundBioinformatics of cardiovascular miRNA biology
Kunz, M., Xiao, K., Liang, C., Viereck, J., Pachel, C., Frantz, S., Thum, T., & Dandekar, T. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.11.027 · Cited by 25
Self-citation
Metadata
- Authors
- Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., Remke, J., Caprio, M., Jentzsch, C., Engelhardt, S., Geisendorf, S., Glas, C., Hofmann, T. G., Nessling, M., Richter, K., Schiffer, M., Carrier, L., Napp, L. C., Bauersachs, J., Chowdhury, K., & Thum, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- IRCCS San Raffaele Roma (IT)
- Technical University of Munich (DE)
- Max Planck Institute for Biophysical Chemistry (DE)
- German Cancer Research Center (DE)
- Mount Desert Island Biological Laboratory (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Chowdhury, Kamal
- Thum, Thomas
- ORCID
- Venue
- Nature Communications
- Published
- 2012-09-25
- Volume
- 3
- Issue
- 1
- Pages
- 1078-1078
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3657998
- OpenAlex
- W2101080348
- Cited by
- 610
- References
- 46
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 47 · 2023: 32 · 2022: 60 · 2021: 53 · 2020: 52 · 2019: 41 · 2018: 43 · 2017: 51 · 2016: 47 · 2015: 67 · 2014: 44 · 2013: 26
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Baden-Württemberg Stiftung
- Deutsches Krebsforschungszentrum
- Deutsche Forschungsgemeinschaft (DFG-TH903/10-1, 01EO0802, SCHI587/3)
- Bundesministerium für Bildung und Forschung (01EO0802)
- Max-Planck-Gesellschaft
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- miR-212, miR-132, cardiac hypertrophy, cardiomyocyte autophagy, heart failure, FOXO3, pressure overload, antagomir, cardiomyocyte-specific overexpression, starvation-induced autophagy
- MeSH terms
- Antagomirs, Animals, Autophagy, Cells, Cultured, Cardiomegaly, Male, Mice, Transgenic, Oligonucleotides, Calcineurin, Reverse Transcriptase Polymerase Chain Reaction, Myocytes, Cardiac, MicroRNAs, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.